Peripartum Cardiomyopathy
Details of the Concept
Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy defined as new-onset heart failure with systolic dysfunction (LV ejection fraction <45%) presenting in the final months of pregnancy or in the postpartum period in a woman without previously known heart disease and without an identifiable reversible cause. It is a significant cause of maternal morbidity and mortality. PPCM and dilated cardiomyopathy (DCM) may represent conditions within a spectrum of shared pathophysiology, making distinction diagnostically important but sometimes challenging.
Key Facts
Definition and Diagnosis
- Diagnostic criteria: New-onset cardiomyopathy with EF <45%, near end of pregnancy or postpartum, in a woman without prior heart disease, without reversible cause (excluding myocarditis, hypertension, toxin-induced, ischemia, valve disease) sources/cv-pregnancy-aha-2020 (rating: high)
- Reversible causes that must be excluded: myocarditis, hypertension-related, underlying valve disease, toxin-induced, ischemia
- Echocardiography is the primary diagnostic tool; LV dilatation and systolic dysfunction typical
Prognosis — IPAC Study
- IPAC study (Investigations of Pregnancy Associated Cardiomyopathy; n=100): followed women with PPCM with serial echocardiography during the first postpartum year sources/cv-pregnancy-aha-2020 (rating: high)
- Recovery of LV function occurred almost exclusively within the first 6 months postpartum; little subsequent change after 6 months
- Major cardiovascular events (heart transplantation, LV assist device implantation, or death) occurred almost exclusively in women with EF <30% at presentation
- Prognosis is therefore strongly linked to EF at presentation: EF <30% is the critical high-risk threshold
Pathophysiology and Mechanism
- Multiple proposed causes; animal models implicate suppression of prolactin production in preventing PPCM development sources/cv-pregnancy-aha-2020 (rating: high)
- PPCM and DCM share pathophysiological features; some cases may represent a spectrum of the same underlying condition
- Bromocriptine (dopamine agonist) suppresses prolactin production and has been associated with improved LV function in studies
Treatment
Heart failure management during pregnancy and postpartum:
- Diuretics for volume control
- Nitrates and/or hydralazine for afterload reduction
- β-blockers and/or digoxin for rate/rhythm control
- Anticoagulation if indicated (EF very low, intracardiac thrombus)
- Bromocriptine: adjunctive treatment per the 2018 ESC guidelines for management of CVD during pregnancy (COR 2a in ESC); may be considered alongside standard HF therapy sources/cv-pregnancy-aha-2020 (rating: high)
Contraception and Future Pregnancy Counseling
- Contraception must be discussed early and before discharge from the peripartum admission sources/cv-pregnancy-aha-2020 (rating: high)
- Risk of recurrent PPCM in future pregnancies must be explicitly counseled
- Contraception guidance (per CDC Medical Eligibility Criteria):
- IUD (copper or hormonal): reasonable in all PPCM (normal/mild dysfunction and moderate-severe dysfunction)
- Progestin-only implant/pill: reasonable in all PPCM
- Combined hormonal contraception (CHC): unreasonable even in PPCM with normal/mild systolic dysfunction (risk outweighs benefit)
Overlap with DCM and HCM Management
- Women with preexisting DCM may decompensate during pregnancy and be mistaken for PPCM; careful history and prior echo records required
- HCM in pregnancy: up to 23% develop HF or arrhythmia-related complications in third trimester or postpartum; diuretics must be used cautiously (preload dependence in LVOTO) sources/cv-pregnancy-aha-2020 (rating: high)
Contradictions / Open Questions
- Bromocriptine evidence base: Supporting studies are small and/or non-randomized; ESC COR 2a is based on limited data; the large randomized trial needed to confirm benefit is still lacking sources/cv-pregnancy-aha-2020 (rating: high)
- PPCM vs DCM boundary: Whether PPCM is a distinct entity or pregnancy-unmasked DCM is not fully resolved; genetic overlap with DCM genes (e.g., TTN truncating variants) exists but penetrance in pregnancy context is uncertain
- Future pregnancy risk: Quantification of recurrent PPCM risk in women who recover LV function vs those with residual dysfunction is imprecise; currently estimated at 20–50% depending on baseline EF recovery
- Anticoagulation threshold: No consensus on EF cutoff at which to initiate prophylactic anticoagulation in PPCM in the absence of intracardiac thrombus
Connections
- Related to concepts/Cardio-Obstetrics — PPCM is the cardiomyopathy most directly managed by the cardio-obstetrics team
- Related to entities/DCM — PPCM may be a pregnancy-unmasked DCM; TTN truncating variants are shared risk factor
- Related to entities/Heart-Failure — PPCM management follows HF principles with pregnancy-specific adaptations
- Related to entities/Maternal-Health-Disparities — Black women have increased arrhythmia frequency during pregnancy; racial mortality disparities in maternal CVD extend to cardiomyopathy
- Related to concepts/Adverse-Pregnancy-Outcomes — PPCM is an adverse cardiovascular event of pregnancy; preeclampsia aOR 3.3 for PPCM
- Related to concepts/Preeclampsia — preeclampsia is a risk factor for PPCM (aOR 3.3)